Cargando…
Towards Fixed Dosing of Tocilizumab in ICU-Admitted COVID-19 Patients: Results of an Observational Population Pharmacokinetic and Descriptive Pharmacodynamic Study
BACKGROUND AND OBJECTIVE: In the randomized controlled trial REMAP-CAP, it was shown that next to dexamethasone, the interleukin (IL)-6 receptor antagonist tocilizumab improves outcome, including survival in intensive care unit (ICU)-admitted coronavirus disease 2019 (COVID)-19 patients. Therefore t...
Autores principales: | Moes, Dirk Jan A. R., van Westerloo, David J., Arend, Sandra M., Swen, Jesse J., de Vries, Annick, Guchelaar, Henk-Jan, Joosten, Simone A., de Boer, Mark G. J., van Gelder, Teun, van Paassen, Judith |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502793/ https://www.ncbi.nlm.nih.gov/pubmed/34633645 http://dx.doi.org/10.1007/s40262-021-01074-2 |
Ejemplares similares
-
Tamoxifen pharmacokinetics and pharmacodynamics in older patients with non-metastatic breast cancer
por: Souwer, E. T. D., et al.
Publicado: (2023) -
Comparison of the Impact of Pharmacogenetic Variability on the PK of Slow Release and Immediate Release Tacrolimus Formulations
por: van Gelder, Teun, et al.
Publicado: (2020) -
The Clinical Impact of the C(0)/D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients
por: van Gelder, Teun, et al.
Publicado: (2020) -
A Review of Mathematical Models for Tumor Dynamics and Treatment Resistance Evolution of Solid Tumors
por: Yin, Anyue, et al.
Publicado: (2019) -
Tocilizumab in ICU-admitted COVID-19 Patients: A Retrospective Study
por: Siami, Zeinab, et al.
Publicado: (2023)